Inc280: Clinical Trials

2 trials of Inc280, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Terminated 2

Follow Inc280: new trials by email Literature Review of Inc280 trials Research Report on Inc280

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy
Capmatinib, Osimertinib, Pemetrexed - Carcinoma, Non-Small-Cell Lung
Phase 3TerminatedNovartis Pharmaceuticals62021-09-222024-03-05
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
Capmatinib, Docetaxel - Carcinoma, Non-Small-Cell Lung
Phase 3TerminatedNovartis Pharmaceuticals222020-09-252025-05-16

Conditions studied

Carcinoma, Non-Small-Cell Lung (2)  ·  Carcinoma (1)

Sponsors

Novartis Pharmaceuticals (2)

Countries

South Korea (2)  ·  Belgium (1)  ·  Brazil (1)  ·  Bulgaria (1)  ·  France (1)  ·  Germany (1)  ·  Hungary (1)  ·  India (1)  ·  Italy (1)  ·  Japan (1)  ·  Lithuania (1)  ·  Malaysia (1)  ·  Netherlands (1)  ·  Portugal (1)  ·  Russia (1)